This article is more than 5 years old. Information may no longer be current.
Five important news items from the EULAR Annual Congress
Click Here to Manage Email Alerts
Healio Rheumatology features the top five stories and videos from the EULAR Annual Congress. More of Healio Rheumatology’s live coverage, including video interviews with researchers, can be found by clicking here.
Study: Systemic ultrasound in the management of early rheumatoid arthritis is not justified
LONDON — The systemic use of ultrasound in the follow-up of patients with early rheumatoid arthritis is not justified, based on results of the ARCTIC trial which were presented here at the EULAR Annual Congress. Read more.
Antibodies to biological infliximab cross-reacted with infliximab biosimilars
LONDON — Findings presented at the EULAR Annual Congress showed antibodies to infliximab in patients who received the biological treatment cross-reacted with infliximab biosimilars. Read more.
VIDEO: A look at results from phase 3 studies of baricitinib for RA treatment
LONDON — At the EULAR Annual Congress, Peter C. Taylor, MA, PhD, FRCP, discussed a study that looked at phase 3 studies of baricitinib. He said the patient-reported outcomes showed statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA). Watch more.
VIDEO: Rituximab does not increase malignancy rates in patients with rheumatoid arthritis
LONDON — At the EULAR Annual Congress, Matthew D. Cascino, MD, discussed a study that found patients with rheumatoid arthritis treated with rituximab did not have increased malignancy rates. Watch more.
Study: Hyperuricemia may increase mortality risk for patients with gout, cardiovascular disease
LONDON — Hyperuricemia increased the cardiovascular disease mortality risk in patients with gout and existing cardiovascular disease, according to data presented here at the EULAR Annual Congress. Read more.